Literature DB >> 11433348

Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis.

S Bátkai1, Z Járai, J A Wagner, S K Goparaju, K Varga, J Liu, L Wang, F Mirshahi, A D Khanolkar, A Makriyannis, R Urbaschek, N Garcia, A J Sanyal, G Kunos.   

Abstract

Advanced cirrhosis is associated with generalized vasodilation of unknown origin, which contributes to mortality. Cirrhotic patients are endotoxemic, and activation of vascular cannabinoid CB1 receptors has been implicated in endotoxin-induced hypotension. Here we show that rats with biliary cirrhosis have low blood pressure, which is elevated by the CB1 receptor antagonist SR141716A. The low blood pressure of rats with CCl4-induced cirrhosis was similarly reversed by SR141716A, which also reduced the elevated mesenteric blood flow and portal pressure. Monocytes from cirrhotic but not control patients or rats elicited SR141716A-sensitive hypotension in normal recipient rats and showed significantly elevated levels of anandamide. Compared with non-cirrhotic controls, in cirrhotic human livers there was a three-fold increase in CB1 receptors on isolated vascular endothelial cells. These results implicate anandamide and vascular CB1 receptors in the vasodilated state in advanced cirrhosis and indicate a novel approach for its management.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11433348     DOI: 10.1038/89953

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  96 in total

1.  Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.

Authors:  Sándor Bátkai; Pál Pacher; Zoltán Járai; Jens A Wagner; George Kunos
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-04-01       Impact factor: 4.733

Review 2.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

3.  Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography.

Authors:  Garth E Terry; Jussi Hirvonen; Jeih-San Liow; Nicholas Seneca; Johannes T Tauscher; John M Schaus; Lee Phebus; Christian C Felder; Cheryl L Morse; Victor W Pike; Christer Halldin; Robert B Innis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-24       Impact factor: 9.236

4.  Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors.

Authors:  M Domenicali; J Ros; G Fernández-Varo; P Cejudo-Martín; M Crespo; M Morales-Ruiz; A M Briones; J-M Campistol; V Arroyo; E Vila; J Rodés; W Jiménez
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 5.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

6.  Cirrhotic cardiomyopathy: an endocannabinoid connection?

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

Review 7.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

8.  Hepatorenal syndrome.

Authors:  Charles K F Ng; Michael H M Chan; Morris H L Tai; Christopher W K Lam
Journal:  Clin Biochem Rev       Date:  2007-02

9.  Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis.

Authors:  Mohanraj Rajesh; Hao Pan; Partha Mukhopadhyay; Sándor Bátkai; Douglas Osei-Hyiaman; György Haskó; Lucas Liaudet; Bin Gao; Pál Pacher
Journal:  J Leukoc Biol       Date:  2007-07-25       Impact factor: 4.962

Review 10.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.